Ongoing trials in amyloidosis

1 Views

07/08/23

Angela Dispenzieri, MD, of the Mayo Clinic, Rochester, MN, gives an overview of the current clinical trials underway researching treatment methods of amyloidosis. Dr Dispenzieri discusses a re-emerging therapeutic strategy, amyloid-targeted antibodies, which was previously discontinued due to a lack of benefit from agents such as NEOD001. Dr Dispenzieri also talks of ongoing trials investigating BCL-2 inhibition in the refractory setting for light-chain amyloidosis and discusses the prospects of antibody-drug conjugates, a treatment method which is increasingly gaining attention. This interview took place during the ninth annual meeting of the Society of Hematologic Oncology (SOHO 2021) congress.